Openness and transparency are important considerations for medicines regulators, where public health is of paramount concern. As part of their commitment to transparency, the European Medicines Agency (EMA) and Therapeutic Goods Administration (TGA) in Australia publish information relating to their evaluation of medicines via public assessment reports. European Public Assessment Reports (EPARs) and Australian Public Assessment Reports (AusPARs) provide information about the considerations that led the regulator to approve or refuse the application. The reports summarise assessments by each regulator of the information provided on the quality, safety, and efficacy of the medicine under evaluation. Here, we describe the experiences of two es...
In recent years, European pharmaceutical regulators have increasingly committed to heightening acces...
In Europe and North America, there is increasing political pressure being put on health regulatory a...
Chemicals provide us with many benefits but can also have adverse effects on human health and the en...
Openness and transparency are important considerations for medicines regulators, where public health...
Over the past 10 years, European pharmaceutical regulators (especially the European Medicines Agency...
Over the past 10years, European pharmaceutical regulators (especially the European Medicines Agency ...
The concept of transparency has gained widespread appeal in the European pharmaceutical domain, not ...
The concept of transparency has gained widespread appeal in the European pharmaceutical domain, not ...
Based on an analysis of relevant laws and policies, regulator data portals, and information requests...
Following a review process lasting almost four years, and culminating in several pieces of new Europ...
Following a review process lasting almost four years, and culminating in several pieces of new Europ...
The Chapter outlines the relevant provisions governing access to information concerning quality, saf...
In the arena of pharmaceutical drug regulation, transparency is the favoured focus of many current p...
In recent years, European pharmaceutical regulators have increasingly committed to heightening acces...
In recent years, European pharmaceutical regulators have increasingly committed to heightening acces...
In Europe and North America, there is increasing political pressure being put on health regulatory a...
Chemicals provide us with many benefits but can also have adverse effects on human health and the en...
Openness and transparency are important considerations for medicines regulators, where public health...
Over the past 10 years, European pharmaceutical regulators (especially the European Medicines Agency...
Over the past 10years, European pharmaceutical regulators (especially the European Medicines Agency ...
The concept of transparency has gained widespread appeal in the European pharmaceutical domain, not ...
The concept of transparency has gained widespread appeal in the European pharmaceutical domain, not ...
Based on an analysis of relevant laws and policies, regulator data portals, and information requests...
Following a review process lasting almost four years, and culminating in several pieces of new Europ...
Following a review process lasting almost four years, and culminating in several pieces of new Europ...
The Chapter outlines the relevant provisions governing access to information concerning quality, saf...
In the arena of pharmaceutical drug regulation, transparency is the favoured focus of many current p...
In recent years, European pharmaceutical regulators have increasingly committed to heightening acces...
In recent years, European pharmaceutical regulators have increasingly committed to heightening acces...
In Europe and North America, there is increasing political pressure being put on health regulatory a...
Chemicals provide us with many benefits but can also have adverse effects on human health and the en...